Michel de Rosen, President & CEO of ViroPharma Incorporated, presides over the opening bell.

Friday May 18, 2007
ViroPharma Incorporated

ViroPharma Incorporated
[VPHM]

ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(r) approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at www.viropharma.com.

Reprints

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 05/02/2007 Download Hi-Res Quality Photo of this NASDAQ Market Open - Pictured: Michel de Rosen, President & CEO of ViroPharma Incorporated, presides over the opening bell. Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at Jolene.Libretto@nasdaq.com. Kindly credit © 2007, The Nasdaq Stock Market, Inc. Reprinted with permission. © Copyright 2007, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.